Epcoritamab + Epcoritamab, lenalidomide and rituximab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Large B-cell Lymphoma
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Trial Timeline
May 14, 2024 → May 1, 2028
NCT ID
NCT06414148About Epcoritamab + Epcoritamab, lenalidomide and rituximab
Epcoritamab + Epcoritamab, lenalidomide and rituximab is a phase 2 stage product being developed by AbbVie for Relapsed/Refractory Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06414148. Target conditions include Relapsed/Refractory Large B-cell Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Large B-cell Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06414148 | Phase 2 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Large B-cell Lymphoma